A Phase II, Multicenter, Open Label Study to Evaluate the Pharmacodynamics of Nivolumab in Combination with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors

Trial Profile

A Phase II, Multicenter, Open Label Study to Evaluate the Pharmacodynamics of Nivolumab in Combination with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Aug 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Bladder cancer; Brain cancer; Head and neck cancer; Hodgkin's disease; Malignant melanoma; Non-small cell lung cancer; Prostate cancer; Solid tumours
  • Focus Biomarker; Pharmacodynamics
  • Acronyms IPINIVO
  • Sponsors Agenus
  • Most Recent Events

    • 19 Aug 2017 Status changed from not yet recruiting to recruiting.
    • 22 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top